A ten-year experience with the diagnosis of von Willebrand disease in Mexico based on a cost-effective strategy.

Background: Von Willebrand disease (VWD), is the most common inherited bleeding disorder worldwide, but its diagnosis is complicated, expensive, and poorly evaluated in several countries.

Objective: To report our long-term experience with the diagnosis of VWD based on a cost-effective strategy.

Methods: We studied 802 Mexican patients, men and women, children, and adults, with clinical suspicion of VWD.

Factor XII Deficiency in Mexico: High Prevalence in the General Population and Patients with Venous Thromboembolic Disease.

Introduction: Thrombosis is one of the leading causes of morbidity and mortality worldwide. Venous thromboembolic disease (VTD) is considered a new epidemic. FXII deficiency is supposed to be a cause of thrombosis.

The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System.

The antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by a hypercoagulability associated to vascular thrombosis and/or obstetric morbidity, is caused by the presence of antiphospholipid antibodies such as lupus anticoagulant, anti-β-2-glycoprotein 1, and/or anticardiolipin antibodies. In the obstetrical APS, antiphospholipid antibodies induce the production of proinflammatory cytokines and tissue factor by placental tissues and recruited neutrophils. Moreover, antiphospholipid antibodies activate the complement system which, in turn, induces a positive feedback leading to recruitment of neutrophils as well as activation of the placenta.

Analysis of the quality of anticoagulation with vitamin K antagonists in three clinical scenarios in Mexico.

Introduction: Vitamin K antagonists (VKA) are a therapeutic alternative in patients with venous thromboembolic disease; however, numerous factors affect their pharmacology.

Objective: To evaluate the quality of VKA anticoagulation at three different time periods in Mexico.

Methods: Prospective study, nested in patient cohorts at three different clinical scenarios between 2013 and 2019.

Abo Blood Group, Atherothrombotic Comorbidities, and COVID-19: A Case-Control Study of their Association in the Mexican Population.

Background: COVID-19 has been associated with negative results in patients with A blood group and with a better evolution in O blood group individuals.

Aim: Because the evidence regarding ABO blood groups and COVID was empirically not that clear in our country, we tested the association regarding COVID-19 and blood groups.

Material And Methods: Adult patients were enrolled in this prospective, case-control, observational multicenter study.